Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.66 +0.26 (+0.45%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.83B
Shares
153.07M
Volume · Oct 29 1M Avg daily vol (3M) 1.89M

Tg Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Tg Therapeutics, Inc. (TGTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-14
Tg Therapeutics, Inc. (TGTX) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-03
Tg Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
Confident tone Azercel allogeneic CAR-T program Capital allocation and share repurchases Enhanced trial and dosing simplification
Revenue
$240.34M
▲ 70.3% YoY
Diluted EPS
$0.05
▼ 70.6% YoY
Gross margin
82.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Tg Therapeutics, Inc. (TGTX) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Tg Therapeutics, Inc. (TGTX) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Tg Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
Confident tone Operating expenses and gross-to-net dynamics Long-term franchise outlook and patent runway Pipeline expansion beyond MS
Revenue
$204.92M
▲ 69.6% YoY
Diluted EPS
$0.12
▲ 300% YoY
Gross margin
83.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Tg Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
Confident tone BRIANVI/Breyanvy U.S. sales growth Multiple sclerosis market positioning Enhanced dosing Phase III program
Revenue
$192.57M*
▲ 78% YoY
Gross margin
80.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Tg Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript
Confident tone BRIUMVI commercial performance Pipeline expansion (ENHANCE and subcu) 2026 outlook and guidance
Revenue
$161.71M
▲ 92.8% YoY
Diluted EPS
$2.43
▲ 12050% YoY
Gross margin
82.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Tg Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
Confident tone Sub-Q Briumvy development Net sales and guidance Growth-to-net and pricing dynamics
Revenue
$141.15M
▲ 92.1% YoY
Diluted EPS
$0.17
▲ 325% YoY
Gross margin
86.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Tg Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
Confident tone BRIUMVI commercial launch momentum Raised 2025 revenue guidance Competitive positioning vs other anti-CD20s
Revenue
$120.86M
▲ 90.4% YoY
Diluted EPS
$0.03
Gross margin
87.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Tg Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript
Confident tone BRIUMVI Commercial Performance ENHANCE Study / Patient Experience Improvements Subcutaneous BRIUMVI Development
Revenue
$108.19M*
▲ 146% YoY
Gross margin
85.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Tg Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
Confident tone BRIUMVI commercial launch and sales growth Pipeline expansion (azer-cel CAR-T, non-MS indications) Capital allocation and share buybacks
Revenue
$83.88M
▼ 49.4% YoY
Diluted EPS
$0.02
▼ 97.3% YoY
Gross margin
88.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Tg Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript
Confident tone BRIUMVI Commercial Launch and Sales Azer-cel CAR-T for Autoimmune Diseases ENHANCE Switch Study
Revenue
$73.47M
▲ 357% YoY
Diluted EPS
$0.04
Gross margin
88.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Tg Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript
Confident tone Briumvi U.S. commercial performance VA contract and market access Azer-cel CAR T partnership and pipeline expansion
Revenue
$63.47M
▲ 713.5% YoY
Diluted EPS
$-0.07
Gross margin
91.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Tg Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
Confident tone BRIUMVI commercial launch and revenue ramp Pipeline expansion / azer-cel partnership BRIUMVI lifecycle management (subcutaneous, enhanced dosing)
Revenue
$43.97M*
▲ 54184% YoY
Gross margin
82.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Tg Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript
Revenue
$165.81M
▲ 176298.9% YoY
Diluted EPS
$0.73
Gross margin
97.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Tg Therapeutics, Inc. (TGTX) Q2 2023 Earnings Call Transcript
Revenue
$16.07M
▲ 2606.1% YoY
Diluted EPS
$-0.34
Gross margin
88.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-01
Tg Therapeutics, Inc. (TGTX) Q1 2023 Earnings Call Transcript
Revenue
$7.80M
▲ 287.1% YoY
Diluted EPS
$-0.28
Gross margin
89.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Tg Therapeutics, Inc. (TGTX) Q4 2022 Earnings Call Transcript
Revenue
$81,000*
▼ 96.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Tg Therapeutics, Inc. (TGTX) Q3 2022 Earnings Call Transcript
Revenue
$94,000
▼ 95.4% YoY
Diluted EPS
$-0.26
Gross margin
97.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Tg Therapeutics, Inc. (TGTX) Q2 2022 Earnings Call Transcript
Revenue
$594,000
▼ 61.6% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Tg Therapeutics, Inc. (TGTX) Q4 2021 Earnings Call Transcript
Revenue
$2.32M*
▲ 6007.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Tg Therapeutics, Inc. (TGTX) Q3 2021 Earnings Call Transcript
Revenue
$2.03M
▲ 5242.1% YoY
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-02
Tg Therapeutics, Inc. (TGTX) Q2 2021 Earnings Call Transcript
Revenue
$1.54M
▲ 3965.8% YoY
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Tg Therapeutics, Inc. (TGTX) Q1 2021 Earnings Call Transcript
Revenue
$793,000
▲ 1986.8% YoY
Diluted EPS
$-0.69
Gross margin
82.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Tg Therapeutics, Inc. (TGTX) Q4 2020 Earnings Call Transcript
Revenue
$38,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Tg Therapeutics, Inc. (TGTX) Q3 2020 Earnings Call
Revenue
$38,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Tg Therapeutics, Inc. (TGTX) Q2 2020 Earnings Call Transcript
Revenue
$38,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-03
Tg Therapeutics, Inc. (TGTX) Q4 2019 Earnings Call
Revenue
$38,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 118 filings 112 filers Visit website Investor relations